Please assess the completion status of the following clinical trial:

Trial Title: Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of Blepharokeratoconjunctivitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must have a clinical diagnosis of BKC in at least one eye~* Subjects must be willing to discontinue contact lens use for the duration of the study~* Subjects who are able and willing to comply with all treatment and follow- up/study procedures.~Exclusion Criteria:~* Subjects participating in any drug or device clinical investigation within 30 days prior to entry into this study and/or during the period of study participation.~* Subjects who have any uncontrolled systemic disease or debilitating disease.~* Subjects who have a known hypersensitivity to the study drugs or their components (including benzalkonium chloride) or contraindications to tobramycin or ocular corticosteroids.~* Subjects who use any topical or systemic ophthalmic medications listed as disallowed in the study protocol, within the specified time frame prior to Visit 1.~* Subjects who have a disease or conditions which the Investigator determines could interfere with the safety and efficacy evaluations of the study drug.~* Subjects having ocular surgery (including laser surgery) in either eye within the past three months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Loteprednol and tobramycin (Type: EXPERIMENTAL): Loteprednol etabonate and tobramycin ophthalmic suspension
- Tobramycin and dexamethasone (Type: ACTIVE_COMPARATOR): Tobramycin and dexamethasone ophthalmic suspension

Based on this trial design, predict the completion outcome and termination type (if applicable).